MTOR and neoplasm: Four compounds, methotrexate and pralatrexate (folate antagonists), temsirolimus (mTOR inhibitor), and GSK2126458 (PI3K inhibitor), were confirmed to reduce tumour size, but did not synergize with trametinib at the various doses tested (Figs S1 and S2), and therefore were not further analysed.